We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial.
- Authors
Vickers, Madge R; Martin, Jeannett; Meade, Tom W; WISDOM study team
- Abstract
At the time of feasibility work and final design of the trial there was no randomised control trial evidence for the long-term risks and benefits of hormone replacement therapy. Observational studies had suggested that long term use of estrogen was likely to be associated, amongst other things, with reduced risks of osteoporosis and ischaemic heart disease and increased risks of breast and endometrial cancer. Concomitant use of progestogens had been shown to protect against endometrial cancer, but there were few data showing how progestogen might affect estrogen actions on other conditions. Disease specific risks from observational studies suggested that, overall, long-term HRT was likely to be beneficial. Several studies showed that mortality from all causes was lower in HRT users than in non-users. Some secondary cardiovascular prevention trials were ongoing but evidence was also required for a range of outcomes in healthy women. The WISDOM trial was designed to compare combined estrogen and progestogen versus placebo, and estrogen alone versus combined estrogen and progestogen. During the development of WISDOM the Women's Health Initiative trial was designed, funded and started in the US.
- Publication
BMC women's health, 2007, Vol 7, p2
- ISSN
1472-6874
- Publication type
Journal Article
- DOI
10.1186/1472-6874-7-2